Sanofi Consumer Healthcare India Limited — Q4 FY25 earnings call

Call held 24 Mar 2026

Management summary

Sanofi Consumer Healthcare India Limited reported robust financial performance for FY25, with significant growth in revenue, operating profit, and PAT. The company highlighted its strong brand portfolio and current profitability metrics, while outlining strategic plans to double doctor reach and direct retail coverage by 2026. Management also detailed efforts in organizational building, innovation, and post-recall recovery, emphasizing a clear focus on profitable growth and penetration in the Indian market.

Highlights

  • Revenue from Operations grew by 21%, Operating Profit by 13%, and PAT increased by 33% in FY25.

  • Current turnover is close to ₹880 crore, with Profit from Operations at 37% and ROCE at 62.5%.

  • Strong legacy brands like Avil, Allegra, Combiflam, and DePURA hold top positions in their respective categories.

  • Successful post-recall recovery, with products quickly returning to leadership positions and pre-recall run rates.

  • Committed to social responsibility with initiatives like Project Amrit (clean water for 200,000 people) and Van Mitra (CO2 reduction), and certified as a B-Corp organization.

Concerns

  • Past product recalls temporarily impacted market share and provided opportunities for competitors.

  • HCP reach and channel space were historically under-leveraged, requiring significant investment to scale up.

  • Distribution of key brands was largely through indirect channels, limiting direct control and range selling.

Key financials

2 periods

Headline

  • Turnover (Current)
    ₹880 Cr
  • Profit from Operations Margin (Current)
    37%
  • ROCE (Current)
    62.5%

FY25 YoY Growth

  • Revenue from Operations
    —
    YoY +21%
  • Operating Profit
    —
    YoY +13%
  • PAT
    —
    YoY +33%

What they filed

Q1 FY27: revenue up 6.8%, net profit up 13.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue160 171 173 221 234 +46%251 +47%229 +32%236 +7%
EBITDA63 62 64 70 85 +35%90 +45%89 +39%89 +27%
Net profit45 44 50 61 63 +40%66 +50%68 +36%69 +13%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

HCP Reach

  • Doctor Reach (Face-to-Face) HCP Reach · 2026 · High confidence Double
    So, we plan to double our doctor reach face to face. I'm not talking about the online reach. That, of course, will be way higher with the number of campaigns that we do. But from where we are, we plan to double the reach to HCPs. ... So that's 2026 itself. ... This year itself, yeah.

    — Mr. Himanshu Bakshi

Retail Coverage

  • Direct Retail Coverage Retail Coverage · 2026 · High confidence 2X
    Increasing direct retail coverage. So, we've got very clearly certain programs running for which we need to win in the store. Multiple display points and visibility points in store, that's something that we've started working on. And, of course, increasing our direct coverage also by 2X. ... So that's 2026 itself. ... This year itself, yeah.

    — Mr. Himanshu Bakshi

HCP Engagement

  • Digital Reach (HCPs) HCP Engagement · Medium confidence 50,000 HCPs
    Digital reach in addition to 50,000 HCPs, from where we are today, to really scale up our HCP engagement efforts in the category.

    — Mr. Himanshu Bakshi

What to watch in Q1 FY26

Doctor Reach (Face-to-Face)

By end of 2026
Current Not specified, but 'from where we are today'
Target Doubled

Why it matters

Key strategic pillar for growth and market penetration, indicating expansion of direct engagement with HCPs.

So, we plan to double our doctor reach face to face.

Risks & concerns

  • Impact of past product recalls

    medium

    Past product recalls led to temporary market absence and provided opportunities for competitors, though recovery is strong.

    Management acknowledged

  • Regulatory uncertainty regarding OTC policy

    medium

    The OTC policy is still in the works, and its finalization is seen as a significant 'unlock' for direct consumer communication.

    Analyst acknowledged

Q&A highlights

5 direct
Growth vs. Profitability Focus for India Direct
I think if you ask me one answer to this, it's very clearly growth and penetration that we want to achieve in India. And that's where the global group is completely aligned.

Clarifies the company's primary strategic objective for the Indian market, emphasizing growth and penetration over pure profitability.

Asked by Ms. Monica - SBI Mutual Funds

Future Product Pipeline and Unlisted Products Partial
On your second question, which is about the other products which are not a part of the listed entity, yes, these discussions continue to happen with the group. Of course, once we have a discussion with the board, we will come back to all of you. But as of now, the decision is to continue with what we have right now.

Indicates potential for future product additions from the parent company but no immediate plans for unlisted products to join the listed entity.

Asked by Mr. Saurabh Kapadia - Sundaram Mutual Funds

Impact of OTC Regulations on Direct Consumer Communication Direct
I think the biggest unlock will be direct consumer communication, you know, the moment OTC comes in, and then that gives us the freedom to really, again, build the category from where we want to today, which is today a constraint as we speak.

Highlights the significant opportunity and strategic shift that potential OTC regulations could bring for direct consumer engagement and category building.

Asked by Mr. Shiv - ASK Mutual Fund

Inorganic Growth Opportunities Partial
I think the key question that we need to answer there is what are we wanting to look at from an inorganic perspective? And I think that's a discussion we keep having with the group.

Confirms that inorganic growth is a consideration, but the company is still evaluating strategic fit and market multiples.

Asked by Mr. Shiv - ASK Mutual Fund

Balance between Margins and Growth (FMCG approach) Direct
I think for us, sustainable, profitable growth will always be the agenda, right? Today, when you look at our portfolios with the virtue of wherever we are today, we have increased our spends. And if you really look at the margins also today, we've not had a significant downside there.

Clarifies the company's balanced approach to growth and profitability, emphasizing sustainable growth without significant margin erosion despite increased spending.

Asked by Mr. Shiv - ASK Mutual Fund

Post-Recall Market Share Regain and Practitioner Feedback Direct
So, of course, if you're out of the market for more than a year, it definitely had an impact. It also gave opportunity for other brands to come in and take our space. I think what's worked well for us since we've come back is one, we are very quickly getting back to almost the same run rate that we were before we had the recall.

Provides an update on the recovery trajectory post-recalls, indicating a strong return to previous run rates and positive practitioner feedback.

Asked by Mr. Hitesh Mahida - HDFC Life

Diversification of Contract Manufacturing Organizations (CMOs) Direct
Yes, I think if you really look at our overall CMO network today, it's very well covered. Absolutely no issue that we foresee in terms of any production or any supplies in the future.

Addresses concerns about supply chain resilience and dependence, confirming a robust and diversified CMO network.

Asked by Mr. Hitesh Mahida - HDFC Life

2 min read 6 chapters

Detailed narrative

Overall Business Performance & Strategic Focus

Sanofi Consumer Healthcare India Limited reported a strong financial year 2025, with Revenue from Operations growing by 21%, Operating Profit by 13%, and PAT by 33%. The company currently boasts a turnover of approximately ₹880 crore, with a Profit from Operations margin of 37% and a ROCE of 62.5%. Management emphasized a clear focus on 'growth and penetration' for India, aligning with the global group's objectives, while ensuring this growth remains profitable.

Demerger, Organizational Building & Culture

The demerger process led to building a new, empowered organization focused on profitable growth. This involved restructuring, reorganizing, and hiring top talent from the FMCG world, resulting in a leadership team with diverse experience. The company fostered a strong KPI-driven performance culture and was recognized as a preferred workplace, particularly for women, with female employee diversity more than doubling in the last year.

Brand Portfolio & Market Leadership

The company operates with a portfolio of strong legacy brands like Avil (number one in volume), Allegra (number three in value), Combiflam (top five), and DePURA (top five in Vitamin D). These brands hold leading positions in their respective categories, offering significant headroom for growth. The strategy involves winning through brand equity by investing behind these brands for future relevance and continued service to the Indian population.

Growth Levers: HCPs, Consumers & Retail

Sanofi Consumer Healthcare is focusing on synergistic demand generation through both Healthcare Professionals (HCPs) and direct consumer engagement. Plans include doubling face-to-face doctor reach and increasing direct retail coverage by 2X by the end of 2026. The company is also investing in consumer education, leveraging social media, and ensuring pharmacists are well-informed about its brands, moving from low single-digit to mid-teens investment in advertising and promotion (ANP).

Innovation & Digital Transformation

Innovation is a key pillar, with the company leveraging its global R&D network and local dedicated teams. The launch of Allegra D, a unique formulation for congestion, exemplifies this focus on meaningful new innovations. The company has also invested significantly in Digital and AI, enabling functions to be more productive and ensuring that creatives are AI-enabled for faster turnaround and better content generation.

Post-Recall Recovery & Supply Chain Resilience

Following past product recalls, the company has successfully brought all affected products back to market, quickly regaining leadership positions and returning to pre-recall run rates for most brands. Management reported positive feedback from HCPs, reinforcing the perceived superiority of their products. Furthermore, the company has established a robust and diversified Contract Manufacturing Organization (CMO) network, ensuring no foreseeable issues with production or supplies.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls